175 related articles for article (PubMed ID: 12105163)
1. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
[TBL] [Abstract][Full Text] [Related]
2. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
[TBL] [Abstract][Full Text] [Related]
3. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
Wachtell K; Rokkedal J; Bella JN; Aalto T; Dahlöf B; Smith G; Roman MJ; Ibsen H; Aurigemma GP; Devereux RB
Am J Cardiol; 2001 Jan; 87(1):54-60. PubMed ID: 11137834
[TBL] [Abstract][Full Text] [Related]
4. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
5. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
6. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction.
Olsen MH; Wachtell K; Borch-Johnsen K; Okin PM; Kjeldsen SE; Dahlöf B; Devereux RB; Ibsen H
J Hum Hypertens; 2002 Aug; 16(8):591-5. PubMed ID: 12149666
[TBL] [Abstract][Full Text] [Related]
7. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients.
Muiesan ML; Salvetti M; Monteduro C; Rizzoni D; Corbellini C; Castellano M; Porteri E; Agabiti-Rosei E
J Hypertens; 2000 Nov; 18(11):1651-6. PubMed ID: 11081779
[TBL] [Abstract][Full Text] [Related]
8. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Wachtell K; Gerdts E; Palmieri V; Olsen MH; Nieminen MS; Papademetriou V; Boman K; Dahlöf B; Aurigemma GP; Rokkedal JE; Devereux RB
J Hypertens; 2010 Jul; 28(7):1541-6. PubMed ID: 20410835
[TBL] [Abstract][Full Text] [Related]
9. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
[TBL] [Abstract][Full Text] [Related]
12. Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Wachtell K; Papademetriou V; Smith G; Gerdts E; Dahlöf B; Engblom E; Aurigemma GP; Bella JN; Ibsen H; Rokkedal J; Devereux RB
Am Heart J; 2004 Sep; 148(3):538-44. PubMed ID: 15389245
[TBL] [Abstract][Full Text] [Related]
13. Effect of regression of left ventricular hypertrophy from systemic hypertension on systolic function assessed by midwall shortening (HOT echocardiographic study).
Zabalgoitia M; Rahman SN; Haley WE; Yarows S; Krause L; Anderson LC; Oraby MA; Amarena J
Am J Cardiol; 2001 Sep; 88(5):521-5. PubMed ID: 11524061
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular midwall mechanics in subjects with aortic stenosis and normal systolic chamber function.
Ballo P; Mondillo S; Motto A; Faraguti SA
J Heart Valve Dis; 2006 Sep; 15(5):639-50. PubMed ID: 17044369
[TBL] [Abstract][Full Text] [Related]
15. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
[TBL] [Abstract][Full Text] [Related]
17. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
18. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study).
Palmieri V; Bella JN; DeQuattro V; Roman MJ; Hahn RT; Dahlof B; Sharpe N; Lau CP; Chen WC; Paran E; de Simone G; Devereux RB
Am J Cardiol; 1999 Sep; 84(5):558-62. PubMed ID: 10482155
[TBL] [Abstract][Full Text] [Related]
19. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
[TBL] [Abstract][Full Text] [Related]
20. Changes in left ventricular geometry during antihypertensive treatment.
Salvetti M; Paini A; Bertacchini F; Stassaldi D; Aggiusti C; Agabiti Rosei C; Bassetti D; Agabiti-Rosei E; Muiesan ML
Pharmacol Res; 2018 Aug; 134():193-199. PubMed ID: 29959031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
